ClinicalTrials.gg
CompletedNCT00632931Updated Jul 30, 2015Results posted

A Crossover Study to Assess the Effects of Vorinostat (MK0683, SAHA) in Patients With Advanced Cancer (0683-070)(COMPLETED)

A Phase 1 interventional study of vorinostat and Comparator: placebo (unspecified) in Advanced Cancer Relapsed and Advanced Cancer Refractory, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-07-30.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

A 2-period, crossover study to assess the effects of MK0683 (vorinostat) on the QTc interval in patients with relapsed or refractory advanced cancer.

Read the detailed description

Merck Duration of Treatment : vorinostat; treatment will continue until disease progression or intolerable toxicity is reached

02

Conditions studied

  • Advanced Cancer Relapsed
  • Advanced Cancer Refractory
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient has a -confirmed or locally advanced solid tumor that has failed to respond to standard therapy, progressed despite standard therapy or for which standard therapy does not exist
  • Patient has of greater than 3 months
  • Patient is able to swallow capsules

Exclusion criteria

Exclusion Criteria:

  • Patient has had chemotherapy, radiotherapy or biological therapy 2 weeks prior to taking study drug
  • Patient is currently participating or has participated in a study with an compound or device within 30 days of signing
  • Patient has active and/or carcinomatous meningitis
  • Patient has primary central nervous system tumor
  • Patient has a history of drug or alcohol abuse
  • Patient has or C
  • Patient is positive
  • Patient has active infection or has received intravenous antibiotics, antiviral or antifungal agents 2 weeks before taking study drug
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    A

    Arm A: Drug/Placebo

    Drug: vorinostat · Drug: Comparator: placebo (unspecified)

  • Experimental
    B

    Arm B: Placebo/Drug

    Drug: vorinostat · Drug: Comparator: placebo (unspecified)

Interventions

  • A 2-part, crossover study. Part 1: Arm A: Single dose of vorinostat 800 mg capsules (Period 1) crossing over to Single dose of vorinostat Placebo capsules (Period 2) Arm B: Single dose of vorinostat Placebo capsules (Period 1) crossing over to Single dose of vorinostat 800 mg capsules (Period 2). Part 2: All patients will receive 400 mg vorinostat capsules once daily. Treatment will continue until disease progression or intolerable toxicity.

    Also known as: MK0683, Zolinza®

  • DrugComparator: placebo (unspecified)

    A 2-part, crossover study. Part 1: Arm A: Single dose of vorinostat Placebo capsules (Period 2) Arm B: Single dose of vorinostat Placebo capsules (Period 1).

06

What researchers measure

Primary outcomes

  1. Change From Baseline in QTcF at 0.5 Hours

    The Fridericia correction of the QT interval (QTcF) was determined at each time point from five replicate measurements. The change from baseline in QTcF was calculated by subtracting the QTcF value at each timepoint from the QTcF baseline (predose) value.

    Time frame: Baseline and 0.5 hours

  2. Change From Baseline in QTcF at 1 Hour

    Fridericia correction of the QT interval (QTcF) was determined at each time point from five replicate measurements. The change from baseline in QTcF was calculated by subtracting the QTcF value at each timepoint from the QTcF baseline (predose) value.

    Time frame: Baseline and 1 hour

  3. Change From Baseline in QTcF at 2 Hours

    The Fridericia correction of the QT interval (QTcF) was determined at each time point from five replicate measurements. The change from baseline in QTcF was calculated by subtracting the QTcF value at each timepoint from the QTcF baseline (predose) value.

    Time frame: Baseline and 2 hours

  4. Change From Baseline in QTcF at 3 Hours

    The Fridericia correction of the QT interval (QTcF) was determined at each time point from five replicate measurements. The change from baseline in QTcF was calculated by subtracting the QTcF value at each timepoint from the QTcF baseline (predose) value.

    Time frame: Baseline and 3 hours

  5. Change From Baseline in QTcF at 4 Hours

    The Fridericia correction of the QT interval (QTcF) was determined at each time point from five replicate measurements. The placebo-corrected change from baseline in QTcF was calculated by subtracting the QTcF change from baseline for placebo at each timepoint from the QTcF change from baseline for vorinostat at each timepoint.

    Time frame: Baseline and 4 hours

  6. Change From Baseline in QTcF at 8 Hours

    The Fridericia correction of the QT interval (QTcF) was determined at each time point from five replicate measurements. The change from baseline in QTcF was calculated by subtracting the QTcF value at each timepoint from the QTcF baseline (predose) value.

    Time frame: Baseline and 8 hours

  7. Change From Baseline in QTcF at 12 Hours

    The Fridericia correction of the QT interval (QTcF) was determined at each time point from five replicate measurements. The change from baseline in QTcF was calculated by subtracting the QTcF value at each timepoint from the QTcF baseline (predose) value.

    Time frame: Baseline and 12 hours

  8. Change From Baseline in QTcF at 24 Hours

    The Fridericia correction of the QT interval (QTcF) was determined at each time point from five replicate measurements. The change from baseline in QTcF was calculated by subtracting the QTcF value at each timepoint from the QTcF baseline (predose) value.

    Time frame: Baseline and 24 hours

07

Results

Posted Feb 15, 2010

Participant flow

Eric Rubin, M.D., The Cancer Institute of New Jersey, New Brunswick, New Jersey; Pamela Munster, M.D., H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida; Prof. Dr. Simon van Belle, University Hospital of Ghent, Ghent, Belgium. Dosing initiated on 16-Jul-2007 and completed on 05-Feb-2009.

Part 1, Period 1
Participant flow — Part 1, Period 1
MilestoneVorinostat Then Placebo: Part 1Placebo Then Vorinostat: Part 1All Participants: Part 2
Started13120
Completed11120
Not completed200
Withdrew: Protocol violation100
Withdrew: Withdrawal by subject100
Part 1, Washout
Participant flow — Part 1, Washout
MilestoneVorinostat Then Placebo: Part 1Placebo Then Vorinostat: Part 1All Participants: Part 2
Started11120
Completed11120
Not completed000
Part 1, Period 2
Participant flow — Part 1, Period 2
MilestoneVorinostat Then Placebo: Part 1Placebo Then Vorinostat: Part 1All Participants: Part 2
Started11120
Completed11120
Not completed000
Post-Part 1 Washout
Participant flow — Post-Part 1 Washout
MilestoneVorinostat Then Placebo: Part 1Placebo Then Vorinostat: Part 1All Participants: Part 2
Started12120
Completed12120
Not completed000
Part 2
Participant flow — Part 2
MilestoneVorinostat Then Placebo: Part 1Placebo Then Vorinostat: Part 1All Participants: Part 2
Started0024
Completed000
Not completed0024
Withdrew: Adverse event003
Withdrew: Death001
Withdrew: Lack of efficacy0017
Withdrew: Withdrawal by subject003

Outcome measures

PrimaryChange From Baseline in QTcF at 0.5 Hours

The Fridericia correction of the QT interval (QTcF) was determined at each time point from five replicate measurements. The change from baseline in QTcF was calculated by subtracting the QTcF value at each timepoint from the QTcF baseline (predose) value.

Time frame:
Baseline and 0.5 hours
Reported as:
Mean · milliseconds
Change From Baseline in QTcF at 0.5 Hours
millisecondsVorinostatPlacebo
Change From Baseline in QTcF at 0.5 Hours1.78 (-1.53 to 5.09)-1.22 (-4.53 to 2.08)
Statistical analysis
  • Vorinostat vs Placebo · Mean difference (final values): 3.00 · 90% CI -0.28 to 6.28
PrimaryChange From Baseline in QTcF at 1 Hour

Fridericia correction of the QT interval (QTcF) was determined at each time point from five replicate measurements. The change from baseline in QTcF was calculated by subtracting the QTcF value at each timepoint from the QTcF baseline (predose) value.

Time frame:
Baseline and 1 hour
Reported as:
Mean · milliseconds
Change From Baseline in QTcF at 1 Hour
millisecondsVorinostatPlacebo
Change From Baseline in QTcF at 1 Hour0.22 (-3.09 to 3.52)-1.23 (-4.54 to 2.08)
Statistical analysis
  • Vorinostat vs Placebo · Mean difference (final values): 1.45 · 90% CI -1.38 to 4.72
PrimaryChange From Baseline in QTcF at 2 Hours

The Fridericia correction of the QT interval (QTcF) was determined at each time point from five replicate measurements. The change from baseline in QTcF was calculated by subtracting the QTcF value at each timepoint from the QTcF baseline (predose) value.

Time frame:
Baseline and 2 hours
Reported as:
Mean · milliseconds
Change From Baseline in QTcF at 2 Hours
millisecondsVorinostatPlacebo
Change From Baseline in QTcF at 2 Hours1.09 (-2.22 to 4.40)-1.98 (-5.23 to 1.28)
Statistical analysis
  • Vorinostat vs Placebo · Mean difference (final values): 3.07 · 90% CI -0.17 to 6.31
PrimaryChange From Baseline in QTcF at 3 Hours

The Fridericia correction of the QT interval (QTcF) was determined at each time point from five replicate measurements. The change from baseline in QTcF was calculated by subtracting the QTcF value at each timepoint from the QTcF baseline (predose) value.

Time frame:
Baseline and 3 hours
Reported as:
Mean · milliseconds
Change From Baseline in QTcF at 3 Hours
millisecondsVorinostatPlacebo
Change From Baseline in QTcF at 3 Hours1.32 (-1.99 to 4.63)-1.52 (-4.77 to 1.73)
Statistical analysis
  • Vorinostat vs Placebo · Mean difference (final values): 2.84 · 90% CI -0.40 to 6.08
PrimaryChange From Baseline in QTcF at 4 Hours

The Fridericia correction of the QT interval (QTcF) was determined at each time point from five replicate measurements. The placebo-corrected change from baseline in QTcF was calculated by subtracting the QTcF change from baseline for placebo at each timepoint from the QTcF change from baseline for vorinostat at each timepoint.

Time frame:
Baseline and 4 hours
Reported as:
Mean · milliseconds
Change From Baseline in QTcF at 4 Hours
millisecondsVorinostatPlacebo
Change From Baseline in QTcF at 4 Hours4.95 (1.64 to 8.26)-1.49 (-4.75 to 1.76)
Statistical analysis
  • Vorinostat vs Placebo · Mean difference (final values): 6.44 · 90% CI 3.21 to 9.68
PrimaryChange From Baseline in QTcF at 8 Hours

The Fridericia correction of the QT interval (QTcF) was determined at each time point from five replicate measurements. The change from baseline in QTcF was calculated by subtracting the QTcF value at each timepoint from the QTcF baseline (predose) value.

Time frame:
Baseline and 8 hours
Reported as:
Mean · milliseconds
Change From Baseline in QTcF at 8 Hours
millisecondsVorinostatPlacebo
Change From Baseline in QTcF at 8 Hours-3.56 (-6.87 to -0.25)-7.89 (-11.20 to -4.58)
Statistical analysis
  • Vorinostat vs Placebo · Mean difference (final values): 4.33 · 90% CI 1.05 to 7.60
PrimaryChange From Baseline in QTcF at 12 Hours

The Fridericia correction of the QT interval (QTcF) was determined at each time point from five replicate measurements. The change from baseline in QTcF was calculated by subtracting the QTcF value at each timepoint from the QTcF baseline (predose) value.

Time frame:
Baseline and 12 hours
Reported as:
Mean · milliseconds
Change From Baseline in QTcF at 12 Hours
millisecondsVorinostatPlacebo
Change From Baseline in QTcF at 12 Hours1.35 (-2.08 to 4.78)-1.31 (-4.62 to 2.00)
Statistical analysis
  • Vorinostat vs Placebo · Mean difference (final values): 2.66 · 90% CI -0.70 to 6.02
PrimaryChange From Baseline in QTcF at 24 Hours

The Fridericia correction of the QT interval (QTcF) was determined at each time point from five replicate measurements. The change from baseline in QTcF was calculated by subtracting the QTcF value at each timepoint from the QTcF baseline (predose) value.

Time frame:
Baseline and 24 hours
Reported as:
Mean · milliseconds
Change From Baseline in QTcF at 24 Hours
millisecondsVorinostatPlacebo
Change From Baseline in QTcF at 24 Hours1.53 (-1.84 to 4.98)-4.89 (-8.29 to -1.67)
Statistical analysis
  • Vorinostat vs Placebo · Mean difference (final values): 6.51 · 90% CI 3.19 to 9.82

Adverse events

Collected over Reported adverse experiences are those from the time patients began study treatment until the patient discontinued. The average AE reporting timeframe is 78 days.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All Participants—11/25 (44%)24/25 (96%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventAll Participants
Disease ProgressionGeneral disorders3/25
Abdominal PainGastrointestinal disorders2/25
VomitingGastrointestinal disorders2/25
PyrexiaGastrointestinal disorders2/25
AnemiaBlood and lymphatic system disorders1/25
AscitesGastrointestinal disorders1/25
ConstipationGastrointestinal disorders1/25
DiarrheaGastrointestinal disorders1/25
Small Intestinal ObstructionGastrointestinal disorders1/25
FatigueGeneral disorders1/25
Most frequent other events
Showing 10 of 117
Most frequent other events
EventAll Participants
NauseaGastrointestinal disorders20/25
FatigueGeneral disorders17/25
AnorexiaMetabolism and nutrition disorders16/25
ConstipationGastrointestinal disorders12/25
VomitingGastrointestinal disorders10/25
DiarrheaGastrointestinal disorders9/25
CoughRespiratory, thoracic and mediastinal disorders8/25
ThrombocytopeniaBlood and lymphatic system disorders7/25
Dry MouthGastrointestinal disorders6/25
Taste ChangedNervous system disorders6/25

Baseline characteristics

Age, Continuous
Age, Continuous(years)All Participants
Mean59.4 (29 to 78)
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female12
Male13
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)All Participants
Asian1
Black2
Hispanic1
White21
Cancer Type
Cancer Type(Participants)All Participants
Ovarian5
Colon3
Lung3
Mesothelioma3
Uterine2
Soft Tissue2
Anal1
Basocellular1
Breast1
Gastrointestinal1
Mucinous carcinoma1
Pancreatic1
Thyroid1
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)All Participants
0 = Normal Activity9
1 = Symptoms, but ambulatory13
2 = In bed <50% of the time3
Number of Prior Radiation Therapies
Number of Prior Radiation Therapies(Participants)All Participants
None14
One Prior Radiation Therapy7
Two Prior Radiation Therapies1
Three or More Prior Radiation Therapies3
Number of Prior Systemic Anti-Cancer Therapies
Number of Prior Systemic Anti-Cancer Therapies(Participants)All Participants
One Prior Systemic Anti-Cancer Therapy0
Two Prior Systemic Anti-Cancer Therapies3
Three or more Prior Systemic Anti-Cancer Therapies22
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Munster PN, Rubin EH, Van Belle S, Friedman E, Patterson JK, Van Dyck K, Li X, Comisar W, Chodakewitz JA, Wagner JA, Iwamoto M. A single supratherapeutic dose of vorinostat does not prolong the QTc interval in patients with advanced cancer. Clin Cancer Res. 2009 Nov 15;15(22):7077-84. doi: 10.1158/1078-0432.CCR-09-1214. Epub 2009 Nov 3. PubMed 19887475 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2007, a primary completion of May 2008 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2010, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 29, 2008
First posted
Mar 11, 2008
Start
Jul 2007
Primary completionActual
May 2008
CompletionActual
Apr 2009
Results first posted
Feb 15, 2010
Last update
Jul 30, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00632931
Responsible party
Sponsor
First posted
Mar 11, 2008
Start date
Jul 2007
Primary completion
May 2008
Completion
Apr 2009
Results posted
Feb 15, 2010
Last update
Jul 30, 2015

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vorinostat

Start the discussion